| 余阳阳,杜 方,马佳良,李嘉正,白 锋,孙守刚.血清HO-1、ESM-1与急性ST段抬高型心肌梗死合并2型糖尿病患者冠脉病变和主要不良心血管事件的关系[J].,2024,(21):4197-4200 |
| 血清HO-1、ESM-1与急性ST段抬高型心肌梗死合并2型糖尿病患者冠脉病变和主要不良心血管事件的关系 |
| Relationship between Serum HO-1, ESM-1 and Coronary Artery Disease and Major Adverse Cardiovascular Events in Patients with Acute ST-Segment Elevation Myocardial Infarction Combined with Type 2 Diabetes Mellitus |
| 投稿时间：2024-05-24 修订日期：2024-06-18 |
| DOI：10.13241/j.cnki.pmb.2024.21.044 |
| 中文关键词: 急性ST段抬高型心肌梗死 2型糖尿病 血红素氧合酶-1 内皮细胞特异性分子-1 冠脉病变 主要不良心血管事件 |
| 英文关键词: Acute ST-segment elevation myocardial infarction Type 2 diabetes mellitus Heme oxygenase-1 Endothelial cell specific molecule-1 Coronary artery disease Major adverse cardiovascular events |
| 基金项目:甘肃省科技计划项目（23JRRA1005） |
|
| 摘要点击次数: 55 |
| 全文下载次数: 25 |
| 中文摘要: |
| 摘要 目的：探讨血清血红素氧合酶-1（HO-1）、内皮细胞特异性分子-1（ESM-1）与急性ST段抬高型心肌梗死（ASTEMI）合并2型糖尿病（T2DM）患者冠脉病变和主要不良心血管事件（MACE）的关系。方法：选取177例行经皮冠状动脉介入治疗术的ASTEMI合并T2DM患者（T2DM组），另选取同期未合并T2DM的ASTEMI患者90例（非T2DM组）和同期体检健康者90例（对照组）。ASTEMI合并T2DM患者根据Gensini评分分为73例轻度冠脉病变组、63例中度冠脉病变组、41例重度冠脉病变组，根据经皮冠状动脉介入治疗术后6个月是否发生MACE分为MACE组（63例）和非MACE组（114例）。以ASTEMI合并T2DM患者MACE发生为因变量，建立多因素Logistic回归模型确定其影响因素。结果：血清HO-1、ESM-1水平T2DM组高于非T2DM组高于健康对照组（P＜0.05）。轻、中、重度冠脉病变组血清HO-1、ESM-1水平依次升高（P＜0.05）。随访6个月，177例ASTEMI合并T2DM患者PCI术后MACE发生率为35.59%（63/177）。ASTEMI合并T2DM患者MACE的独立危险因素为KILLIP分级≥Ⅱ级、Gensini评分高、HO-1高、ESM-1高（P＜0.05）。结论：血清HO-1、ESM-1水平升高与ASTEMI合并T2DM患者冠脉病变加重和MACE发生有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum heme oxygenase-1 (HO-1), endothelial cell specific molecule-1 (ESM-1) and coronary artery disease and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction (ASTEMI) combined with type 2 diabetes mellitus (T2DM). Methods: 177 patients with ASTEMI combine with T2DM (T2DM group) who underwent percutaneous coronary intervention were selected, 90 ASTEMI patients without T2DM (non-T2DM group) and 90 healthy subjects (control group) were selected. patients with ASTEMI combine with T2DM were divided into 73 cases of mild coronary artery disease group, 63 cases of moderate coronary artery disease group and 41 cases of severe coronary artery disease group according to Gensini score, and patients were divided into MACE group (63 cases) and non-MACE group (114 cases) according to whether MACE occurred 6 months after percutaneous coronary intervention. The occurrence of MACE in patients with ASTEMI combine with T2DM as the dependent variable, multivariate Logistic regression model was established to determine the influencing factors. Results: The levels of serum HO-1 and ESM-1 in T2DM group were higher than those in non-T2DM group and healthy control group(P<0.05). The levels of serum HO-1 and ESM-1 in mild, moderate and severe coronary artery disease groups increased in turn(P<0.05). After 6 months of follow-up, the incidence of MACE after PCI in 177 patients with ASTEMI combine with T2DM was 35.59%(63/177). The independent risk factors of MACE in patients with ASTEMI combined with T2DM were KILLIP grade≥II, high Gensini score, high HO-1 and high ESM-1(P<0.05). Conclusion: The increase of serum HO-1 and ESM-1 levels is relate to the aggravation of coronary artery disease and the occurrence of MACE in patients with ASTEMI combine with T2DM. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
